Clareo Health | Pharmacokinetic Study of BMS-914143 in Participants With Normal Renal Function and Mild, Moderate, Severe and End-stage Renal Dysfunction
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bristol-Myers Squibb
Primary purpose: Protocol designed to evaluate the effect of renal impairment on pharmacokinetics of BMS-914143
Age
18–75
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Normal renal function or mild, moderate, severe or end-stage renal dysfunction
You may not be if
History of uncontrolled or unstable cardiovascular, respiratory, gastrointestinal, hepatic, endocrine, hematopoietic, psychiatric or neurological conditions within 6 months of Lambda administration
History of chronic liver disease including cirrhosis, hepatitis B virus (HBV), hepatitis C virus (HCV), primary biliary cirrhosis, etc
History of central nervous system or neuro-psychiatric disease. Subjects with severe depression and/or other uncontrolled psychiatric conditions should not be enrolled in this study
History of of suicide attempt within the 5 years preceding BMS-914143 administration
Inability to tolerate subcutaneous injections
Donation of \>400 mL of blood within 8 weeks or plasma within 4 weeks of planned dosing
